PT2812351T - Composição farmacêutica para o tratamento de esclerose múltipla - Google Patents

Composição farmacêutica para o tratamento de esclerose múltipla

Info

Publication number
PT2812351T
PT2812351T PT137103081T PT13710308T PT2812351T PT 2812351 T PT2812351 T PT 2812351T PT 137103081 T PT137103081 T PT 137103081T PT 13710308 T PT13710308 T PT 13710308T PT 2812351 T PT2812351 T PT 2812351T
Authority
PT
Portugal
Prior art keywords
treatment
pharmaceutical composition
multiple sclerosis
sclerosis
pharmaceutical
Prior art date
Application number
PT137103081T
Other languages
English (en)
Inventor
Selmaj Krzysztof
Szczepanik Marian
Original Assignee
Selmaj Krzysztof
Szczepanik Marian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selmaj Krzysztof, Szczepanik Marian filed Critical Selmaj Krzysztof
Publication of PT2812351T publication Critical patent/PT2812351T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT137103081T 2012-02-10 2013-02-08 Composição farmacêutica para o tratamento de esclerose múltipla PT2812351T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Publications (1)

Publication Number Publication Date
PT2812351T true PT2812351T (pt) 2018-08-01

Family

ID=46762685

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137103081T PT2812351T (pt) 2012-02-10 2013-02-08 Composição farmacêutica para o tratamento de esclerose múltipla

Country Status (9)

Country Link
US (2) US20150080313A1 (pt)
EP (1) EP2812351B1 (pt)
DK (1) DK2812351T3 (pt)
ES (1) ES2684725T3 (pt)
HU (1) HUE039044T2 (pt)
PL (2) PL398077A1 (pt)
PT (1) PT2812351T (pt)
SI (1) SI2812351T1 (pt)
WO (1) WO2013117742A2 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2016414T3 (en) * 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
NO2737906T3 (pt) * 2008-01-25 2018-07-28

Also Published As

Publication number Publication date
DK2812351T3 (en) 2018-07-09
PL398077A1 (pl) 2012-08-27
HUE039044T2 (hu) 2018-12-28
WO2013117742A3 (en) 2014-02-20
US20190201484A1 (en) 2019-07-04
EP2812351A2 (en) 2014-12-17
EP2812351B1 (en) 2018-03-28
US20150080313A1 (en) 2015-03-19
PL2812351T3 (pl) 2018-09-28
SI2812351T1 (sl) 2018-11-30
WO2013117742A2 (en) 2013-08-15
ES2684725T3 (es) 2018-10-04

Similar Documents

Publication Publication Date Title
HK1212632A1 (zh) 用於治療 介導的疾病的藥物組合物
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
SI3378862T1 (sl) Dihidropirimidinoizokuinolini in farmacevtski sestavki le-teh za zdravljenje multiple skleroze
ZA201505443B (en) Compositions containing phorbol esters for the treatment of stroke
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
PL2814462T3 (pl) Kompozycja farmaceutyczna na bazie oleju do leczenia chorób przewodu pokarmowego
PT2812351T (pt) Composição farmacêutica para o tratamento de esclerose múltipla
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
AU2011900519A0 (en) Drug compositions for the treatment of insomnia